{"id":7253,"date":"2020-08-06T07:28:07","date_gmt":"2020-08-06T12:28:07","guid":{"rendered":"https:\/\/cornflowerblue-rail-980953.hostingersite.com\/?p=7253"},"modified":"2020-08-07T06:06:45","modified_gmt":"2020-08-07T11:06:45","slug":"whats-new-in-liver-imaging-turkish-august-2020","status":"publish","type":"post","link":"https:\/\/staging-hub.acoredu.com\/tr\/whats-new-in-liver-imaging-turkish-august-2020\/","title":{"rendered":"What’s new in Liver Imaging (Turkish) – August 2020"},"content":{"rendered":"

HCC (Hepatosell\u00fcler Karsinom)<\/strong><\/span><\/h3>\n

\u00a0<\/strong><\/p>\n

Lee S, Kim Y-Y, Shin J, ve di\u011f. Hepatosel\u00fcler Karsinom i\u00e7in BT ve MRG Karaci\u011fer G\u00f6r\u00fcnt\u00fcleme Raporlama ve Veri Sistemi 2018 Versiyonu: Sistematik Derleme ve Metaanaliz<\/strong><\/span><\/h5>\n

(Lee S, Kim Y-Y, Shin J, et al. J Am Coll Radiol<\/em> [Internet]. Elsevier; 2020 [cited 2020];0.<\/p>\n

Tamam\u0131 i\u00e7in: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154614402030644X<\/a>)<\/p>\n

Anahtar Kelimeler: <\/strong>LI-RADS, tan\u0131 de\u011feri, BT, MRG, HCC<\/p>\n

Klinik Soru: <\/strong>HCC\u2019nin tespitinde LI-RADS ne kadar iyi?<\/p>\n

Ne yap\u0131ld\u0131: <\/strong>LI-RADS v2018\u2019in; her bir\u00a0 LI-RADS kategorisinde (LR1, LR2, LR3, LR4, LR5) HCC saptamas\u0131n\u0131n BT ve MRG ile tan\u0131sal performans\u0131 de\u011ferlendirildi.<\/p>\n

Nas\u0131l Yap\u0131ld\u0131:<\/strong> HCC i\u00e7in LI-RADS v2018’in tan\u0131sal do\u011frulu\u011funu bildiren \u00e7al\u0131\u015fmalar i\u00e7in MEDLINE, Embase ve Scopus’un geriye d\u00f6n\u00fck veritaban\u0131 incelenmi\u015f olup 14 \u00e7al\u0131\u015fman\u0131n meta-analizi yap\u0131lm\u0131\u015ft\u0131r.<\/p>\n

Bulgular: <\/strong>1841\u2019i HCC olmak \u00fczere toplam 2709 inceleme. LR-5’in duyarl\u0131l\u0131\u011f\u0131 % 70\u00a0 ve spesifikli\u011fi % 91\u2019dir. LR1’de ve LR2\u2019de HCC saptanmazken; LR3\u2019\u00fcn %31\u2019inde, LR4\u2019\u00fcn %64\u2019\u00fcnde, LR5\u2019in % 95\u2019inde, LR-TIV\u2019in % 54\u2019\u00fcnde ve LRM\u2019nin % 33\u2019\u00fcnde HCC g\u00f6zlendi.<\/p>\n

Sonu\u00e7:<\/strong> LR kategori numaras\u0131 artt\u0131k\u00e7a HCC bulunma oran\u0131 artar. LI-RADS v2018’in LR5 kategorisi, HCC i\u00e7in orta derecede duyarl\u0131l\u0131\u011fa ve y\u00fcksek spesifisiteye sahiptir.<\/p>\n

\u00c7\u0131kar\u0131m:<\/strong> LI-RADS v2018 iyi bir tan\u0131sal performansa sahip olsa da hala geli\u015ftirilmeye a\u00e7\u0131kt\u0131r.<\/p>\n

 <\/p>\n

LI-RADS 4 veya 5 kategorizasyonu, karar verme s\u00fcre\u00e7leri i\u00e7in klinik olarak anlaml\u0131 olmayabilir: prospektif kohort \u00e7al\u0131\u015fmas\u0131<\/strong><\/span><\/h5>\n

(<\/u>Pinero F, Thompson MA, Telli FD, et al. Annals of Hepatology [Internet]. Elsevier; 2020 [cited 2020];0.<\/p>\n

Tamam\u0131 i\u00e7in: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1665268120300685?via%3Dihub<\/a>)<\/p>\n

Anahtar Kelimeler:<\/strong> LI-RADS, tan\u0131 de\u011feri, BT, MRG, HCC<\/p>\n

Klinik Soru:<\/strong> Latin Amerika’da LI-RADS’\u0131n klinik yarar\u0131 nedir?<\/p>\n

Ne yap\u0131ld\u0131: <\/strong>LI-RADS kategorileri, Arjantin’de bulunan tek bir merkezdeki karaci\u011fer nakli eksplantlar\u0131ndaki histopatolojik bulgularla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131.<\/p>\n

Nas\u0131l Yap\u0131ld\u0131: <\/strong>Karaci\u011fer nakli i\u00e7in listelenen 130 HCC hastas\u0131 ile 2012-2018 y\u0131llar\u0131 aras\u0131 prospektif \u00e7al\u0131\u015fma. BT veya MRG’deki maj\u00f6r nod\u00fcl\u00fcn (NOD1) LI-RADS kategorisi, eksplant patoloji bulgular\u0131 ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131.<\/p>\n

Bulgular:<\/strong> LR-3 NOD1\u2019i olan hastalar\u0131n % 50’sinde HCC g\u00f6zlendi. LR-4 NOD1\u2019 olan hastalar\u0131n % 89’unda HCC saptanm\u0131\u015f olup bunlar\u0131n % 11’inde mikrovask\u00fcler invazyon mevcuttu. Son olarak, LR-5 NOD1 % 77’sinde HCC mevcut olup bunlar\u0131n % 17’sinde mikrovask\u00fcler invazyon saptand\u0131.<\/p>\n

Sonu\u00e7: <\/strong>. Genel olarak LI-RADS kullan\u0131\u015fl\u0131 olmakla birlikte eksplant patolojisi ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda HCC olas\u0131l\u0131\u011f\u0131nda LR-4 ve LR-5 aras\u0131nda anlaml\u0131 bir fark g\u00f6zlenmemi\u015ftir.<\/p>\n

\u00c7\u0131kar\u0131m:<\/strong> Yay\u0131mlanan LI-RADS \u00e7al\u0131\u015fmalar\u0131ndan \u00e7o\u011fu daha y\u00fcksek LR kategorilerinde HCC oran\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 g\u00f6stermesine ra\u011fmen Lee ve arkada\u015flar\u0131n\u0131n ge\u00e7en ay Arjantin’de tek bir merkezde nakil hastalar\u0131yla yapt\u0131klar\u0131 \u00e7al\u0131\u015fmada farkl\u0131 sonu\u00e7lara ula\u015f\u0131ld\u0131. Bu nedenle hasta pop\u00fclasyonuna ba\u011fl\u0131 olarak LR-4 ve LR-5 aras\u0131ndaki bu olas\u0131 belirsizlik g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda LR-4 tedavisi ciddiyetle ele al\u0131nmal\u0131d\u0131r.<\/p>\n

 <\/p>\n

Pediyatrik Hepatoblastom, Hepatosel\u00fcler Karsinom ve Di\u011fer Hepatik Neoplazmlar: Amerikan Radyoloji Koleji Pediatrik Karaci\u011fer Raporlama ve Veri Sistemi (LI-RADS) \u00c7al\u0131\u015fma Grubundan Konsens\u00fcs G\u00f6r\u00fcnt\u00fcleme \u00d6nerileri<\/strong><\/span><\/h5>\n

(Schooler GR, Squires JH, Alazraki A, et al. Radiology [Internet]. Radiological Society of North America ; 2020 [cited 2020];200751.<\/p>\n

Tamam\u0131 i\u00e7in: http:\/\/pubs.rsna.org\/doi\/10.1148\/radiol.2020200751<\/a>)<\/p>\n

Anahtar Kelimeler: <\/strong>MRG, HCC, CEUS, BT, tan\u0131 de\u011feri<\/p>\n

Klinik Soru:<\/strong> Karaci\u011fer neoplazm\u0131ndan \u015f\u00fcphelenilen pediyatrik hastalar i\u00e7in karaci\u011fer g\u00f6r\u00fcnt\u00fclemeyi nas\u0131l standartize edebiliriz?<\/p>\n

Ne yap\u0131ld\u0131: <\/strong>ACR LI-RADS i\u00e7inde bir Pediyatrik \u00c7al\u0131\u015fma Grubu olu\u015fturulmu\u015f ve pediyatrik karaci\u011fer lezyonlar\u0131n\u0131n g\u00f6r\u00fcnt\u00fcleme bulgular\u0131n\u0131n nas\u0131l yorumlanaca\u011f\u0131 ve raporlanaca\u011f\u0131 konusunda \u00f6neriler ve rehberlik konusunda bir fikir birli\u011fi olu\u015fturulmu\u015ftur.<\/p>\n

Nas\u0131l Yap\u0131ld\u0131: <\/strong>Karaci\u011fer g\u00f6r\u00fcnt\u00fclemede yandal sertifikal\u0131 11 pediyatrik radyolog, sistematik ve standart bir skorlama sistemi arac\u0131l\u0131\u011f\u0131yla bu makalede g\u00f6sterilen \u00f6neriler konusunda fikir birli\u011fine vard\u0131.<\/p>\n

Bulgular:<\/strong> Kontrastl\u0131 ultrasonun (CEUS) ne zaman kullan\u0131laca\u011f\u0131, hangi MRG protokol\u00fcn\u00fcn ne zaman kullan\u0131laca\u011f\u0131, BT’nin ne zaman kullan\u0131laca\u011f\u0131 ve biyopsinin rol\u00fc; bu makalede sunulmu\u015f ve \u00fczerlerinde anla\u015fmaya var\u0131lm\u0131\u015ft\u0131r.<\/p>\n

Sonu\u00e7<\/strong>: ACR LI-RADS grubunun alt uzmanl\u0131k b\u00f6l\u00fcm\u00fc taraf\u0131ndan bir araya getirilen hepatoblastoma veya hepatosel\u00fcler karsinomdan \u015f\u00fcphelenilen pediyatrik hastalarda g\u00f6r\u00fcnt\u00fclenme i\u00e7in bir dizi k\u0131lavuz ve \u00f6neri mevcuttur.<\/p>\n

\u00c7\u0131kar\u0131m: Pediatrik bir hastada hepatosel\u00fcler karsinom veya hepatoblastom \u015f\u00fcphesi oldu\u011funda do\u011fru tan\u0131sal ad\u0131mlar\u0131n at\u0131ld\u0131\u011f\u0131ndan emin olmak i\u00e7in bu \u00f6nerilere ba\u015fvurmak yard\u0131mc\u0131 olacakt\u0131r.<\/p>\n

 <\/p>\n

KARAC\u0130\u011eER G\u00d6R\u00dcNT\u00dcLEME TEKN\u0130KLER\u0130<\/span><\/strong><\/h3>\n

 <\/p>\n

Radyografik G\u00fcncelleme:<\/strong> <\/span>Fokal karaci\u011fer kitlelerinin tan\u0131s\u0131nda kontrastl\u0131 ultrason yakla\u015f\u0131m\u0131<\/span> <\/strong><\/h5>\n

(Burrowes DP, Medellin A, Harris AC, et al. Radiographics [Internet]. Radiological Society of North America; 2017 [cited 2020];37:1388\u20131400.<\/p>\n

Tamam\u0131 i\u00e7in: https:\/\/pubs.rsna.org\/doi\/10.1148\/rg.2020200109<\/a>)<\/p>\n

Anahtar Kelimeler: <\/strong>CEUS, tan\u0131 de\u011feri, LI-RADS<\/p>\n

Klinik Soru:<\/strong> 2017-CEUS i\u00e7in LI-RADS’a g\u00f6re, yeti\u015fkin hastalarda t\u00fcm karaci\u011fer nod\u00fcllerinin de\u011ferlendirilmesine y\u00f6nelik bir algoritma nas\u0131l olu\u015fturulur?<\/p>\n

Ne yap\u0131ld\u0131: <\/strong>Burrowes ve arkada\u015flar\u0131, hepatokarsinogenez s\u00fcreci boyunca kan ak\u0131\u015f\u0131 de\u011fi\u015fimine ba\u011fl\u0131 olarak HCC ve \u00f6nc\u00fc nodullerin kontrastlanma \u00f6zelliklerinin nas\u0131l de\u011fi\u015febilece\u011fini a\u00e7\u0131klad\u0131lar. Her nod\u00fcl tipi i\u00e7in g\u00f6r\u00fcnt\u00fcleme bulgular\u0131n\u0131, CEUS LI-RADS kategorileri ile ili\u015fkilendirdiler Bu \u00e7al\u0131\u015fma, 2017’de Burrowes ve arkada\u015flar\u0131 taraf\u0131ndan yay\u0131nlanan ve sadece malign ve malign olmayan t\u00fcm\u00f6rlerin nas\u0131l ay\u0131rt edilece\u011fini ele alan \u00f6nceki algoritmay\u0131 g\u00fcncellemek i\u00e7in yap\u0131lm\u0131\u015ft\u0131r.<\/p>\n

\u00c7\u0131kar\u0131m:<\/strong> CEUS LI-RADS, \u00f6nc\u00fc nod\u00fclleri de kapsayarak HCC riski bulunduran hastalar\u0131n karaci\u011fer incelemelerinin t\u00fcm\u00fcn\u00fc kategorize etmek i\u00e7in kullan\u0131labilir.<\/p>\n

 <\/p>\n

Hepatosel\u00fcler Karsinom Tan\u0131s\u0131nda Kontrastl\u0131 Ultrason-Karaci\u011fer G\u00f6r\u00fcnt\u00fcleme Raporlama ve Veri Sistemi: Tan\u0131sal Performans ve G\u00f6zlemciler Aras\u0131 Uyum<\/span> <\/strong><\/h5>\n

(Zhou H, Zhang C, Du L, et al. Ultraschall Med. 2020 Jul 8. doi:10.1055\/a-1168-6321.<\/p>\n

Tamam\u0131 i\u00e7in: https:\/\/pubmed.ncbi.nlm.nih.gov\/32643777\/<\/a>)<\/p>\n

Anahtar Kelimeler: <\/strong>CEUS, tan\u0131 de\u011feri, LI-RADS<\/p>\n

Klinik Soru:<\/strong> Kontrastl\u0131 ultrason-karaci\u011fer g\u00f6r\u00fcnt\u00fcleme raporlama ve veri sistemi (CEUS-LI-RADS) ne kadar g\u00fcvenilirdir?<\/p>\n

Ne yap\u0131ld\u0131: <\/strong>CEUS \u00f6zelliklerine g\u00f6re belirlenen LI-RADS kategorisi ile 2017 \u00c7in Karaci\u011fer Kanseri K\u0131lavuzu (CLCG), HCC vakalar\u0131 \u00fczerinden kar\u015f\u0131la\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r.<\/p>\n

Nas\u0131l Yap\u0131ld\u0131:<\/strong> Histolojik tan\u0131s\u0131 bulunan 96 y\u00fcksek riskli hasta, 6 g\u00f6zlemci taraf\u0131ndan k\u00f6r bir \u015fekilde prospektif incelenerek, CEUS-LI-RADS kategorisine g\u00f6re de\u011ferlendirildi ve LR5’in tan\u0131sal performans\u0131 ve g\u00f6zlemciler aras\u0131 uyum hesapland\u0131.<\/p>\n

Bulgular:<\/strong> LR5’in duyarl\u0131l\u0131\u011f\u0131 %39-64, do\u011frulu\u011fu %53-71 ve spesifikli\u011fi %93-100 olarak saptand\u0131.\u00a0 CLCG ise %89-100 ile y\u00fcksek duyarl\u0131l\u0131k ve %78-86 ile y\u00fcksek do\u011fruluk oran\u0131na sahipken spesifikli\u011fi %29-64 ile olduk\u00e7a d\u00fc\u015f\u00fck bulundu. CEUS-LI-RADS i\u00e7in okuyucular aras\u0131 orta d\u00fczeyde bir uyum mevcuttu.<\/p>\n

Sonu\u00e7: CEUS-LI-RADS kategori 5, y\u00fcksek riskli hastalarda HCC tan\u0131s\u0131 i\u00e7in y\u00fcksek spesifisitesine ra\u011fmen d\u00fc\u015f\u00fck tan\u0131sal do\u011fruluk de\u011ferleri g\u00f6stermektedir. Ayr\u0131ca, CEUS-LI-RADS ile ilgili g\u00f6zlemciler aras\u0131 uyum tatmin edici d\u00fczeyde de\u011fildir.<\/p>\n

\u00c7\u0131kar\u0131m:<\/strong> G\u00f6zlemciler aras\u0131 uyum, CEUS-LI-RADS i\u00e7in y\u00fcksek olmad\u0131\u011f\u0131ndan, HCC tan\u0131s\u0131nda d\u00fc\u015f\u00fck do\u011fruluk ve duyarl\u0131l\u0131k g\u00f6sterebilir.<\/p>\n

 <\/p>\n

Hepatosell\u00fcler Karsinom\u2019un Non-Invaziv Tan\u0131s\u0131nda Kontrastl\u0131 Ultrason Algoritmalar\u0131 <\/strong>(CEUS-LIRADS\/ESCULAP) \u2013 Prospektif \u00c7oklu Merkezli DEGUM \u00c7al\u0131\u015fmas\u0131<\/strong><\/span><\/h5>\n

Schellhaas B, Bernatik T, Bohle W, et al. Ultraschall Med. 2020 Jul 14. doi: 10.1055\/a-1198-4874. Online ahead of print. PMID: 32663881 Clinical Trial. English.<\/p>\n

Tamam\u0131 i\u00e7in: https:\/\/pubmed.ncbi.nlm.nih.gov\/32663881\/<\/a><\/p>\n

Anahtar Kelimeler: <\/strong>CEUS, tan\u0131 de\u011feri, LI-RADS<\/p>\n

Klinik Soru: <\/strong>Y\u00fcksek riskli hastalarda non-invaziv tan\u0131 y\u00f6ntemi olarak, kontrastl\u0131 ultrasonun (CEUS) tan\u0131sal do\u011frulu\u011fu nedir?<\/p>\n

Ne yap\u0131ld\u0131: <\/strong>Geleneksel CEUS yorumlama, risk grubunda karaci\u011fer lezyon de\u011ferlendirmesi i\u00e7in CEUS: Erlanger g\u00f6r\u00fc\u015f\u00fc (ESCULAP), ve CEUS-LI-RADS kriterlerinin HCC i\u00e7in tan\u0131sal do\u011fruluklar\u0131 kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131<\/p>\n

Nasil yap\u0131ld\u0131: <\/strong>43 merkezden, B-mode ultrasonda tespit edilebilen, histolojik olarak kan\u0131tlanm\u0131\u015f ve hepsinde HCC i\u00e7in y\u00fcksek riskli fokal karaci\u011fer lezyonlar\u0131 bulunan 321 hastan\u0131n prospektif \u00e7al\u0131\u015fmas\u0131.<\/p>\n

Bulgular ve Sonu\u00e7lar: <\/strong>Sirozlu hastalar\u0131n %93\u2019\u00fcnde; CEUS ESCULAP ve geleneksel CEUS s\u0131ras\u0131yla %94 ve %91 ile en y\u00fcksek duyarl\u0131l\u0131\u011fa sahipken, CEUS-LI-RADS %64 ile en d\u00fc\u015f\u00fck duyarl\u0131l\u0131p\u0131 g\u00f6stermi\u015ftir. Ancak CEUS-LI-RADS %79 \u00f6zg\u00fcll\u00fck seviyesine sahipken ESCULAP i\u00e7in %51 ile en d\u00fc\u015f\u00fck \u00f6zg\u00fcll\u00fck oran\u0131 izlendi. Geleneksel CEUS ise %65 \u00f6zg\u00fcll\u00fck oran\u0131 g\u00f6sterdi. CEUS-LI-RADS %34 ile en d\u00fc\u015f\u00fck NPV\u2019e (negatif prediktif de\u011fer)\u00a0 sahipken geleneksel CEUS ve CEUS ESCULAP i\u00e7in ise s\u0131ras\u0131yla %63 ve %67 NPV oran\u0131 saptand\u0131. T\u00fcm modellemelerin PPV (pozitif prediktif de\u011feri) yakla\u015f\u0131k %90 ile y\u00fcksek bulundu.<\/p>\n

Sonu\u00e7: <\/strong>CEUS genel anlamda non-invaziv HCC tan\u0131s\u0131 i\u00e7in tan\u0131sal do\u011frulu\u011fu y\u00fcksek bir y\u00f6ntem olmakla birlikte geleneksel CEUS\u2019un tan\u0131sal do\u011frulu\u011fu neredeyse LI-RADS ve ESCULAP algoritmalar\u0131na e\u015fit bulunmu\u015ftur.<\/p>\n

\u00c7\u0131kar\u0131m: <\/strong>Deneyimli kullan\u0131c\u0131lar i\u00e7in CEUS\u2019un HCC tan\u0131s\u0131 i\u00e7in do\u011frulu\u011funu art\u0131rmak amac\u0131yla ek olarak LI-RADS ya da ESCULAP algoritmalar\u0131n\u0131n kullan\u0131lmas\u0131na ihtiya\u00e7 yoktur.<\/p>\n

 <\/p>\n

KARACIGER: TEMEL BiLiM<\/strong><\/span><\/h3>\n

 <\/p>\n

Rat Modellerinde Karaci\u011fer Fibrozisi ve Non-Alkolik Karaci\u011fer Ya\u011flanmas\u0131na Tedavi Yan\u0131tlar\u0131n\u0131 De\u011ferlendirmede \u0130leri MR G\u00f6r\u00fcnt\u00fclenmesi<\/strong><\/span><\/h5>\n

Zhou IY, Clavijo Jordan V, Rotile NJ, et al. Radiology [Internet]. Radiological Society of North America (RSNA); 2020 [cited 2020];192118.<\/p>\n

Tamam\u0131 i\u00e7in: https:\/\/pubs.rsna.org\/doi\/abs\/10.1148\/radiol.2020192118<\/a><\/p>\n

Anahtar Kelimeler: <\/strong>MR g\u00f6r\u00fcnt\u00fclemesi, fibrozis, Non-Alkolik Karaci\u011fer Ya\u011flanmas\u0131 (NAKY)<\/p>\n

Klinik Soru: <\/strong>G\u00fcn\u00fcm\u00fczde NAKY tan\u0131s\u0131nda standart metot karaci\u011fer biyopsisi olmakla birlikte non-invaziv g\u00f6r\u00fcnt\u00fclemeler ile fibrozis ve NAKY\u2019de tedavi yan\u0131t\u0131n\u0131 ne do\u011frulukta tespit edebiliriz?<\/p>\n

Ne yap\u0131ld\u0131:<\/strong> Farkl\u0131 kontroll\u00fc beslenme ve tedavi \u015femalar\u0131 uygulanan ratlarda, farkl\u0131 seviyelerde NAKY ve tedavi yan\u0131tlar\u0131 olu\u015fturuldu. Bunlar, prospektif olarak g\u00f6r\u00fcnt\u00fcleme ve histolojik analiz i\u00e7in de\u011ferlendirilerek, ileri MR g\u00f6r\u00fcnt\u00fcleme teknikleri i\u00e7in modellemeler olu\u015fturuldu.<\/p>\n

Nas\u0131l yap\u0131ld\u0131:<\/strong> Farkl\u0131 beslenme ve tedavi y\u00f6ntemleri ile 6 gruba ayr\u0131lm\u0131\u015f 66 adet rat modeli kullan\u0131ld\u0131. Elastografi sekans\u0131, T1 sekans\u0131 ve 2 adet de molek\u00fcler hedefli MRI kontrast maddesi (EP-3533-kollajen spesifik ajan) ve Gd-Hyd -allysine hedefli fibrogenez ajan) i\u00e7eren d\u00f6rt adet non-invaziv MR g\u00f6r\u00fcnt\u00fcleme sekanslar\u0131 ile protokol olu\u015fturuldu. Her bir rat karaci\u011ferinde \u00f6nce ROI analizi elde edildi, ard\u0131ndan karaci\u011ferlere y\u00f6nelik histolojik inceleme yap\u0131l\u0131p ROC e\u011frileri ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131.<\/p>\n

Bulgular ve Sonuclar: <\/strong>Her bir fare grup modelinden al\u0131nan patoloji sonu\u00e7lar\u0131 istenen sonu\u00e7lar\u0131 verdi (farkl\u0131 seviyelerde fibrozis, ya\u011flanma ve tedavi yan\u0131t\u0131). ROC analizlerine g\u00f6re\u00a0 kollajen spesifik MR g\u00f6r\u00fcnt\u00fcleme erken d\u00f6nem fibrozis (kollajen birikimi) i\u00e7in en hassas y\u00f6ntem olurken, Gd-Hyd ajan\u0131 aktif hastal\u0131k aktivitesini yans\u0131tan fibrinogenezi saptamada ve derecelendirmede en iyi sonu\u00e7lar\u0131 verdi.<\/p>\n

\u00c7\u0131kar\u0131m:<\/strong> Hedeflenmi\u015f molek\u00fcler MR g\u00f6r\u00fcnt\u00fcleme sistemlerinin NAKY ve fibrozisi saptamada ve derecelendirmede non-invaziv bir y\u00f6ntem olarak biyopsiye alternatif olabilece\u011fi g\u00f6r\u00fcld\u00fc; ancak \u00e7al\u0131\u015f\u0131lan ajanlar\u0131n hen\u00fcz insanlar \u00fczerinde g\u00fcvenli kullan\u0131m\u0131 ispatlanmam\u0131\u015ft\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"HCC (Hepatosell\u00fcler Karsinom) \u00a0 Lee S, Kim Y-Y, Shin J, ve di\u011f. Hepatosel\u00fcler Karsinom i\u00e7in […]","protected":false},"author":3,"featured_media":2955,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[209],"tags":[],"class_list":["post-7253","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-tr"],"yoast_head":"\nWhat's new in Liver Imaging (Turkish) - August 2020 - ACORE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What's new in Liver Imaging (Turkish) - August 2020 - ACORE\" \/>\n<meta property=\"og:description\" content=\"HCC (Hepatosell\u00fcler Karsinom) \u00a0 Lee S, Kim Y-Y, Shin J, ve di\u011f. Hepatosel\u00fcler Karsinom i\u00e7in […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"ACORE\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-06T12:28:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-08-07T11:06:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2030\" \/>\n\t<meta property=\"og:image:height\" content=\"1457\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Abdelrahman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Abdelrahman\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/\",\"url\":\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/\",\"name\":\"What's new in Liver Imaging (Turkish) - August 2020 - ACORE\",\"isPartOf\":{\"@id\":\"https:\/\/staging-hub.acoredu.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg\",\"datePublished\":\"2020-08-06T12:28:07+00:00\",\"dateModified\":\"2020-08-07T11:06:45+00:00\",\"author\":{\"@id\":\"https:\/\/staging-hub.acoredu.com\/#\/schema\/person\/75293c6e4870f3aa293e1394c53df6b7\"},\"breadcrumb\":{\"@id\":\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#primaryimage\",\"url\":\"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg\",\"contentUrl\":\"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg\",\"width\":2030,\"height\":1457},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/staging-hub.acoredu.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What’s new in Liver Imaging (Turkish) – August 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging-hub.acoredu.com\/#website\",\"url\":\"https:\/\/staging-hub.acoredu.com\/\",\"name\":\"ACORE\",\"description\":\"Radiology education for everyone, everywhere!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging-hub.acoredu.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging-hub.acoredu.com\/#\/schema\/person\/75293c6e4870f3aa293e1394c53df6b7\",\"name\":\"Abdelrahman\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/staging-hub.acoredu.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2ad7486277da081678ef5e7172d9abecba77465cd62bd4d7272d1141d0b9bca2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2ad7486277da081678ef5e7172d9abecba77465cd62bd4d7272d1141d0b9bca2?s=96&d=mm&r=g\",\"caption\":\"Abdelrahman\"},\"url\":\"https:\/\/staging-hub.acoredu.com\/tr\/author\/abdelrahman\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"What's new in Liver Imaging (Turkish) - August 2020 - ACORE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/","og_locale":"tr_TR","og_type":"article","og_title":"What's new in Liver Imaging (Turkish) - August 2020 - ACORE","og_description":"HCC (Hepatosell\u00fcler Karsinom) \u00a0 Lee S, Kim Y-Y, Shin J, ve di\u011f. Hepatosel\u00fcler Karsinom i\u00e7in […]","og_url":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/","og_site_name":"ACORE","article_published_time":"2020-08-06T12:28:07+00:00","article_modified_time":"2020-08-07T11:06:45+00:00","og_image":[{"width":2030,"height":1457,"url":"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg","type":"image\/jpeg"}],"author":"Abdelrahman","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Abdelrahman","Tahmini okuma s\u00fcresi":"10 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/","url":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/","name":"What's new in Liver Imaging (Turkish) - August 2020 - ACORE","isPartOf":{"@id":"https:\/\/staging-hub.acoredu.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#primaryimage"},"image":{"@id":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg","datePublished":"2020-08-06T12:28:07+00:00","dateModified":"2020-08-07T11:06:45+00:00","author":{"@id":"https:\/\/staging-hub.acoredu.com\/#\/schema\/person\/75293c6e4870f3aa293e1394c53df6b7"},"breadcrumb":{"@id":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#primaryimage","url":"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg","contentUrl":"https:\/\/staging-hub.acoredu.com\/wp-content\/uploads\/2020\/07\/ct-scan-workstation-with-ct-whole-abdomen-background_t20_ZVGWkj.jpg","width":2030,"height":1457},{"@type":"BreadcrumbList","@id":"https:\/\/staging-hub.acoredu.com\/whats-new-in-liver-imaging-august-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/staging-hub.acoredu.com\/"},{"@type":"ListItem","position":2,"name":"What’s new in Liver Imaging (Turkish) – August 2020"}]},{"@type":"WebSite","@id":"https:\/\/staging-hub.acoredu.com\/#website","url":"https:\/\/staging-hub.acoredu.com\/","name":"ACORE","description":"Radiology education for everyone, everywhere!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging-hub.acoredu.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/staging-hub.acoredu.com\/#\/schema\/person\/75293c6e4870f3aa293e1394c53df6b7","name":"Abdelrahman","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/staging-hub.acoredu.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2ad7486277da081678ef5e7172d9abecba77465cd62bd4d7272d1141d0b9bca2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2ad7486277da081678ef5e7172d9abecba77465cd62bd4d7272d1141d0b9bca2?s=96&d=mm&r=g","caption":"Abdelrahman"},"url":"https:\/\/staging-hub.acoredu.com\/tr\/author\/abdelrahman\/"}]}},"_links":{"self":[{"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/posts\/7253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/comments?post=7253"}],"version-history":[{"count":4,"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/posts\/7253\/revisions"}],"predecessor-version":[{"id":7431,"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/posts\/7253\/revisions\/7431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/media\/2955"}],"wp:attachment":[{"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/media?parent=7253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/categories?post=7253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging-hub.acoredu.com\/tr\/wp-json\/wp\/v2\/tags?post=7253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}